Summary & Overview
HCPCS J3385: Injection, velaglucerase alfa, 100 units
HCPCS Level II code J3385 denotes an injection of velaglucerase alfa in 100-unit increments, a biologic enzyme replacement therapy administered via infusion or injection. Nationally, this code matters for payers and providers managing specialty drug access, prior authorization workflows, site-of-care considerations, and high-cost outpatient drug billing. Payers commonly adjudicate claims for this code in outpatient infusion centers, hospital outpatient departments, and specialty clinics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarked coverage considerations, typical sites of service, and clinical context relevant to billing and reimbursement for velaglucerase alfa. The publication outlines common billing practices, typical administrative hurdles such as prior authorization and medical necessity review, and how the code maps to specialty pharmacy and infusion workflows.
The content provides concise guidance on where J3385 is applied in clinical practice, what stakeholders should expect in payer interactions, and what operational elements—such as unit dosing and infusion site—drive billing. Data not available in the input is noted where applicable, and clinical indications, specific prior authorization criteria, and exact reimbursement rates are not provided here.
Billing Code Overview
HCPCS Level II code J3385 represents an injection of velaglucerase alfa, supplied in 100 unit increments. This service is a pharmacy-administered biologic infusion/injection used in clinical management of relevant enzyme replacement therapy indications.
Service Type: Injectable biologic (velaglucerase alfa)
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or specialty clinic
Clinical & Coding Specifications
Clinical Context
A 34-year-old adult with Gaucher disease type 1 presents to an outpatient infusion center for enzyme replacement therapy. The patient has a documented prescription for velaglucerase alfa dosed in units and arrives for a scheduled intravenous infusion every two weeks. Pre-infusion nursing assessment includes vital signs, review of prior infusion reactions, current weight for dose verification, and confirmation of any premedication orders (e.g., antihistamine, acetaminophen) if prior infusion reactions occurred. Pharmacy verifies the J3385 vial count required to meet the ordered dose and performs aseptic reconstitution and dilution per manufacturer guidelines. During infusion, nursing documents infusion start and stop times, any adverse reactions, and any modifier-applicable circumstances (for example, use of separate billing for drug wastage with modifier JW if wasted drug is discarded). Post-infusion the patient is observed for an appropriate period, discharged with appointment for the next infusion, and clinical documentation includes drug name velaglucerase alfa, total units administered, lot number, expiration date, route (intravenous), and site of service (typically outpatient infusion center or hospital outpatient department).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |